Open AccessEarly hearing threshold changes and peculiarities of audiometric assessments among patients in a drug-resistant tuberculosis treatment center
Author(s) -
Olusola Ayodele Sogebi,
Bolanle O. Adefuye,
Ebenezer Adekunle Ajayi
Publication year - 2021
Publication title -
african health sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.391
H-Index - 44
eISSN - 1729-0503
pISSN - 1680-6905
DOI - 10.4314/ahs.v21i1.30
Subject(s) - medicine , audiogram , ototoxicity , audiometry , absolute threshold of hearing , bone conduction , pure tone audiometry , audiology , prospective cohort study , hearing loss , surgery , chemotherapy , cisplatin
Background Hearing threshold changes occurred relative to baseline at both one and two weeks after onset of aminoglycoside therapy. Objectives To assess changes in audiometric hearing thresholds between pre-treatment values and two weeks into therapy. To document observed changes, and occurrence of ototoxicity within the period. Methods Prospective analytical cohort study on drug-resistant tuberculosis patients. Basic demographic parameters were taken. Three-point audiometric assessments within two weeks into therapy were done. Percentage of patients with ototoxicity were calculated. Pure tone threshold changes between the three audiometric values were compared. Results Audiograms of 53 patients comprising 56.6% males; age range was 13 to 91 years. Both air and bone conduction hearing thresholds significantly worsened between baseline and one week into therapy (p=0.011, and 0.015 respectively), and between baseline and two weeks into therapy (p=0.003 and 0.042 respectively). Minimal insignificant reduction occurred between both air and bone conduction hearing values of week 1 and week 2 of therapy (p= 1.000 and 0.856 respectively). By audiometric criteria, 4 patients (7.5%) developed ototoxicity within two weeks of treatment. Conclusion Audiometric assessments within two weeks into therapy with anti-tuberculous therapy may not represent baseline audiometry. 7.5% of the patients developed ototoxicity within two weeks of therapy.